TF
GALT icon

TimeScale Financial’s Galectin Therapeutics GALT Stock Holding History

TimeScale Financial’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$5.64K Hold
3,920
– – ﹤0.01% 417
2023
Q1 		$8.23K Hold
3,920
– – ﹤0.01% 369
2022
Q4 		$6.39K Hold
3,920
– – ﹤0.01% 357
2022
Q3 		$6K Buy
+3,920
New +$7.32K ﹤0.01% 363

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TimeScale Financial's GALT Position: Q2 2023 in Review

TimeScale Financial held its Galectin Therapeutics (GALT) position steady in Q2 2023 at 3,920 shares worth $5.64K. The position accounts for ﹤0.01% of the portfolio, ranked #417.

TimeScale Financial first reported a position in GALT in Q3 2022 and has held it in 4 quarters since. The position peaked at $8.23K in Q1 2023. 60 funds tracked by Wall St. Rank hold GALT as of Q2 2023.

  • TimeScale Financial held 3,920 shares of Galectin Therapeutics worth $5.64K as of Q2 2023.
  • TimeScale Financial left its Galectin Therapeutics share count unchanged in Q2 2023.
  • Galectin Therapeutics made up ﹤0.01% of TimeScale Financial's portfolio in Q2 2023, its #417 holding.
  • TimeScale Financial first reported a position in Galectin Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • TimeScale Financial's Galectin Therapeutics position peaked at $8.23K in Q1 2023.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.